Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Heart Failure and Impaired Kidney Function: later-stage trial registry

1 of 1 indexed Heart Failure and Impaired Kidney Function trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Heart Failure and Impaired Kidney Function: 1 US clinical trial tracked, 1 recruiting.

Heart Failure and Impaired Kidney Function is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 1 of these trials.

Enrollment posture brief

Registry condition heart-failure-and-impaired-kidney-function

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Heart Failure and Impair (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Heart Failure and Impaired Kidney Function

Heart Failure and Impaired Kidney Function lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Heart Failure and Impaired Kidney Function on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Heart Failure and Impaired Kidney Function is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

AstraZeneca 1 trials

Named interventions

Most-linked intervention names on Heart Failure and Impaired Kidney Function records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin Drug
1 trials
balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg Drug
1 trials
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg Drug
1 trials

US sites by state

Facility locations filed on Heart Failure and Impaired Kidney Function trials. A trial with sites in several states counts in each.

California 1 trials
Arizona 1 trials
Arkansas 1 trials
Alabama 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Heart Failure and Impaired Kidney Function page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Heart Failure and Impaired Kidney Function trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • AstraZeneca sponsors the most Heart Failure and Impaired Kidney Function trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Heart Failure and Impaired Kidney Function condition card totals 1 registered trials; most-linked intervention dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.